Clinical Trial Update: Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels [Phase 4]

View source ↗

Summary

A Phase 4 trial is comparing standard-dose alectinib to dose-adjusted dosing based on blood levels in ALK-positive non-small cell lung cancer, currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alk-positive Non-small Cell Lung Cancer
• Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Alecensa (alectinib)

Snippet

Sponsor: University Medical Center Groningen | Conditions: Drug Monitoring, Carcinoma, Non-Small-Cell Lung | Phase 4 | Status: RECRUITING